The estimated Net Worth of Ken Valenzano is at least $437 Tisíc dollars as of 13 July 2015. Ken Valenzano owns over 15,000 units of Amicus Therapeutics Inc stock worth over $345,842 and over the last 14 years Ken sold FOLD stock worth over $91,229.
Ken has made over 9 trades of the Amicus Therapeutics Inc stock since 2011, according to the Form 4 filled with the SEC. Most recently Ken exercised 15,000 units of FOLD stock worth $225,000 on 13 July 2015.
The largest trade Ken's ever made was buying 25,000 units of Amicus Therapeutics Inc stock on 25 November 2014 worth over $200,000. On average, Ken trades about 4,909 units every 69 days since 2010. As of 13 July 2015 Ken still owns at least 30,687 units of Amicus Therapeutics Inc stock.
You can see the complete history of Ken Valenzano stock trades at the bottom of the page.
Ken's mailing address filed with the SEC is 6 CEDAR BROOK DRIVE, , CRANBURY, NJ, 08512.
Over the last 17 years, insiders at Amicus Therapeutics Inc have traded over $306,740,337 worth of Amicus Therapeutics Inc stock and bought 23,821,602 units worth $176,323,212 . The most active insiders traders include Advisors Llcperceptive Life..., Peter J Barris a Plc Gsk. On average, Amicus Therapeutics Inc executives and independent directors trade stock every 10 days with the average trade being worth of $830,419. The most recent stock trade was executed by Bradley L Campbell on 3 September 2024, trading 7,500 units of FOLD stock currently worth $64,575.
amicus therapeutics is a global, patient-centric biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. we have a unique set of platform technologies and medicines in development for patients living with the lysosomal storage disorders fabry disease and pompe disease and we are committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for these and other rare diseases. the needs of patients in the rare disease community are at the center of our inventive science, our commercial organization, and our clinical programs. our goal throughout all levels of the organization is to make a meaningful difference in the lives of these patients and their caregivers. several opportunities are available to join our team as we build a leading global biotechnology company focused on rare metabolic diseases. our amicus footprint spans 27 countries including our g
Amicus Therapeutics Inc executives and other stock owners filed with the SEC include: